چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| ثمین حمیدی | اول |
| عنوان | متن |
|---|---|
| خلاصه مقاله | Psychiatric disorders remain a significant global health challenge, with traditional treatment approaches often limited by the blood-brain barrier (BBB) and systemic side effects. This review explores the cutting-edge development of stimuli-responsive nanocarriers for nose-to-brain delivery, a revolutionary approach in psychiatric therapeutics. By leveraging the direct pathway from the nasal cavity to the brain and incorporating smart, responsive elements, these advanced nanocarriers aim to enhance drug efficacy, improve targeting, and minimize adverse effects in treating various mental health conditions. Our methodology comprised a comprehensive literature review using major scientific databases, including PubMed, Web of Science, and Scopus. We employed a systematic search strategy with key terms such as 'stimuli-responsive nanocarriers,' 'nose-to-brain delivery,' 'psychiatric disorders,' and 'smart drug delivery systems.' The review focused on recent studies, examining various stimuli-responsive nanocarrier designs, their responsiveness to specific stimuli (e.g., pH, temperature, enzymes), and their efficacy in delivering psychiatric medications via the intranasal route. Results from our analysis reveal significant advancements in the field of stimuli-responsive nanocarriers for nose-to-brain delivery in psychiatric treatment. These smart delivery systems demonstrate remarkable abilities to change their physicochemical properties in response to specific biological triggers, enabling precise control over drug release and targeting. pH-responsive nanocarriers, for instance, showed enhanced drug release in the slightly acidic environment of the brain extracellular space, improving the bioavailability of antidepressants. Temperature-sensitive formulations exhibited improved mucoadhesion and prolonged nasal residence time, facilitating sustained release of anxiolytic drugs. Enzyme-responsive nanocarriers demonstrated targeted delivery of antipsychotics by responding to specific brain enzymes, potentially reducing off-target effects. Notably, these smart nanocarriers showed superior BBB penetration and increased drug concentration in specific brain regions relevant to psychiatric disorders, compared to conventional formulations. Preclinical studies indicated improved therapeutic outcomes, faster onset of action, and reduced systemic side effects across various psychiatric conditions, including depression, anxiety disorders, and schizophrenia. In conclusion, stimuli-responsive nanocarriers for nose-to-brain delivery represent a paradigm shift in psychiatric treatment. By combining the advantages of the nose-to-brain pathway with smart, responsive drug release mechanisms, these advanced delivery systems offer unprecedented control over therapeutic delivery to the brain. The ability to respond to specific biological cues allows for more precise targeting and personalized treatment approaches in managing complex mental health conditions. As this field progresses, future research should focus on optimizing the stimuli-responsive mechanisms for specific psychiatric medications, conducting extensive clinical trials to validate their safety and efficacy in humans, and exploring potential long-term effects of these smart delivery systems. The integration of stimuli-responsive nanocarriers in nose-to-brain delivery holds immense promise for revolutionizing psychiatric pharmacotherapy, potentially leading to more effective, tailored, and patient-friendly treatment options for millions affected by mental health disorders. |
| کلمات کلیدی | Nanocarriers |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| nose to brain poster.pdf | 1403/10/12 | 779461 | دانلود |
| nose to brain.pdf | 1403/10/12 | 253258 | دانلود |
